Circulating Tumor DNA in Peripheral T-cell Lymphomas

Inclusion Criteria: * Patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma. * All primary systemic PTCL entities from the International Consensus Classification 2022. * ≥18 years of age. * Life expectancy of 3 months or longer. * ECOG performance status 0-4 at study entry (PS4 only if lymphoma-induced). * Measurable disease. * Written informed consent. Exclusion Criteria: * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Adult T-cell leukemia / lymphoma * Aggressive NK-cell leukemia * Primary cutaneous T-cell lymphoma such as Sézary syndrome and Mycosis fungoides. * Primary cutaneous CD30 positive T-cell lymphoproliferative disorders. * Lymphomatoid papulosis. * Primary cutaneous anaplastic large cell lymphoma. * Primary cutaneous small/medium CD4-positive T-cell lymphoproliferative disorder. * Primary cutaneous gamma-delta T-cell lymphoma. * Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder. * Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma. * History of active cancer during the past year, except basal cell carcinoma of the skin or stage 0 cervical carcinoma (in situ). * Unwillingness or inability to comply with the study protocol.